The earnings call reflected a strategic shift towards internalization and pipeline expansion, with promising early indicators and additional capital access. However, challenges with Q1 revenue and regulatory hurdles for EUA expansion tempered the outlook.

Company Guidance

In the Invivyd First Quarter 2025 Earnings Conference Call, the company provided detailed guidance on several metrics and strategic initiatives. Invivyd reported Q1 2025 net product revenue of $11.3 million and ended the quarter with cash and cash equivalents of approximately $48 million. The company highlighted its strategic decision to internalize its sales force, leading to a short-term dip in Q1 revenue but promising momentum in Q2. The focus remains on targeting near-term breakeven with continued revenue growth and operating expense management, with Q1 operating expenses reported at $27.4 million, down 15% from Q4 2024. Invivyd also discussed its pipeline expansion, particularly in multiple disease areas beyond COVID-19, including a new discovery program for a measles monoclonal antibody. The company emphasized its disciplined approach to financial management and capital utilization, aiming for profitability by the end of the first half of 2025. They also addressed regulatory interactions and the potential for leveraging surrogate endpoints, such as virus titers, for future approvals, while maintaining a focus on bringing high-value medicines to patients efficiently.

Internalization of Commercial Organization

Invivyd has transitioned to an internal commercial team, aiming for broader adoption of PEMGARDA. Early indicators are promising, targeting near-term breakeven with continued revenue growth.

Additional Non-Dilutive Capital Access

Secured access to additional non-dilutive capital to grow if certain conditions and milestones are met, with a focus on expanding the pipeline to multiple disease areas.

RSV Monoclonal Antibody Development

Initiation of a discovery program for an RSV monoclonal antibody with potential blockbuster commercial potential.

Financial Discipline and Reduction in Operating Expenses

Continued reduction in operating expenses, with a 15% decrease from Q4 2024 to Q1 2025, and a strong cash position and potential access to $30 million in non-dilutive funding.

Positive Q2 Revenue Momentum

Strong revenues reported thus far in Q2, with the highest ever commercial day and week, indicating ongoing growth.

Invivyd (IVVD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IVVD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.07 / -	-0.51	―	―	―
Aug 14, 2025	2025 (Q2)	>-0.01 / -0.12	-0.4	70.00% (+0.28)		―
May 15, 2025	2025 (Q1)	-0.03 / -0.14	-0.38	63.16% (+0.24)
Mar 20, 2025	2024 (Q4)	-0.20 / -0.15	-0.67	77.61% (+0.52)	―	―
Nov 14, 2024	2024 (Q3)	-0.34 / -0.51	-0.36	-41.67% (-0.15)
Aug 14, 2024	2024 (Q2)	-0.37 / -0.40	-0.46	13.04% (+0.06)
May 09, 2024	2024 (Q1)	-0.47 / -0.38	-0.32	-18.75% (-0.06)
Mar 28, 2024	2023 (Q4)	-0.43 / -0.67	-0.41	-63.41% (-0.26)	―	―
Nov 09, 2023	2023 (Q3)	-0.51 / -0.36	-0.42	14.29% (+0.06)
Aug 10, 2023	2023 (Q2)	-0.37 / -0.46	-0.47	2.13% (<+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IVVD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.80	$0.71	-11.25%
May 15, 2025	$0.84	$0.70	-16.67%
Mar 20, 2025	$0.72	$0.74	+2.78%
Nov 14, 2024	$0.89	$0.79	-11.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Invivyd (IVVD) report earnings?

Invivyd (IVVD) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).

What is Invivyd (IVVD) earnings time?

Invivyd (IVVD) earnings time is at Nov 12, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IVVD EPS forecast?

IVVD EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing